The Parainfluenza Virus Infection market is expected to surge due to the disease's increasing prevalence and awareness during ...

"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...

Alteogen Inc. signed its first billion-dollar partnership this year for ALT-B4 technology through two separate contracts with Astrazeneca plc’s U.K.- and U.S.-based Medimmune subsidiaries worth up to ...

The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to ...

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Mesothelioma pipeline landscape. It covers the Mesothelioma ...

MedImmune will explore the target, linker, warhead selection: Do's and Don’ts; five rights of creation of the best optimized fit-for-purpose ADCs; internalisation of ADCs – how to improve ...

Under the terms of the agreement, MedImmune will acquire 100 percent of Definiens’ shares for an initial consideration of $150 million and make additional predetermined milestone payments. Definiens ...

MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen in a deal worth up to US $440 million. Spirogen is a privately-held biotech focused on antibody-drug conjugate ...